Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib

Int J Clin Oncol. 2018 Apr;23(2):400-401. doi: 10.1007/s10147-017-1214-y. Epub 2017 Nov 13.

Author

Ahmet Emre Eskazan¹

Affiliation

¹ Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Fatih, Istanbul, Turkey. [email protected].

PMID: 29134363
DOI: 10.1007/s10147-017-1214-y

No abstract available

Publication types

Letter
Comment

MeSH terms

Dasatinib*
Fusion Proteins, bcr-abl
Humans
Imatinib Mesylate*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein Kinase Inhibitors
Thiazoles

Substances

Protein Kinase Inhibitors
Thiazoles
Imatinib Mesylate
Fusion Proteins, bcr-abl
Dasatinib